Felix Biotechnology, Inc

Centivax, Inc is a biotech company based in South San Francisco, CA, dedicated to accelerating the world's transition to a post-pathogen humanity. They are currently developing a groundbreaking broad-spectrum vaccine for the prevention of all influenza, which has been recognized with a Gates Foundation Grand Challenge End the Pandemic Threat and featured in the Netflix docuseries "Pandemic: How to Prevent an Outbreak." With a focus on pre-clinical development in ferrets and pigs, Centivax aims to revolutionize the field of vaccination and contribute to global health by combatting infectious diseases. Stay updated on their progress by following their CEO, Dr. Jacob Glanville, on social media.Generated from the website

ImYoo is a Public Benefit Corporation based in South San Francisco, CA, dedicated to leveraging breakthrough multi-omic tools to uncover individuals' immune dynamics. With a patient-driven biodiscovery ecosystem, ImYoo conducts patient-centric immune discovery studies by enabling patients to self-collect small volumes of blood at home for high-resolution single-cell genomics assays, aiming to predict kidney transplant rejection and enable precision diagnosis and therapies. By capturing relevant events as they happen and understanding the complexities of diseases, ImYoo strives to advance medical research and technology, offering opportunities for patients, clinicians, researchers, funders, and other stakeholders to participate in their studies and stay updated on their groundbreaking work.Generated from the website

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The company s focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. The company has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. The approach has yielded novel small molecule drug candidates that are in clinical development and two novel small molecule potential drug candidates in development, one in cancer and the other for heart failure. Its most advanced drug candidate, ispinesib is the subject of a Phase II clinical trials program designed to evaluate its effectiveness in many different types of cancer. Cytokinetics is headquartered in South San Francisco.